Companies ›Healthcare ›2508.HK

2508.HK — HKEX Healthcare Facilities & Services

Saint Bella Group Ltd

HK$3,80

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

2,4B HKD

P/E

6,0x

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Saint Bella Group Ltd provides healthcare services and equipment, primarily operating in the biotechnology sector.

Business. Saint Bella Group Ltd (2508.HK) is a healthcare company engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is headquartered in Hong Kong, where it is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryHealthcare Facilities & Services

ActivityBiotechnology

Generated · model-assisted

Sell-side consensus

BUY3 analysts

3 buy0 hold0 sell

Avg 12m price target7,77

Analyst recommendations

3 analysts · consensus Buy

Buy3

Hold0

Sell0

12-month price target

7,77

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

3 analysts · indicative

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 2508.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 2508.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Saint Bella Group Ltd (2508.HK) is a healthcare company engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is headquartered in Hong Kong, where it is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryHealthcare Facilities & Services

ActivityBiotechnology

AI synthesis

GENERATED

Saint Bella Group Ltd has a market capitalization of 2,457,676,175 CNY, with a current market price of 3.95 CNY per share. The company has 622,196,500 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

Profitability and return metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. Therefore, a direct comparison to cohort medians is not possible at this time.

The company's geographic and segmental revenue exposure is not disclosed in the available data, making it difficult to assess revenue concentration or diversification.

Looking ahead, the company's growth trajectory is not quantified in the outlook data. Analysts have provided a mean price target of 7.77 CNY, with a median of 7.77 CNY, suggesting a potential upside from the current market price.

Dilution risk is assessed as low, with no evidence of near-term share issuance or capital-raising activities. The absence of balance-sheet inputs and no going-concern language in source documents prevents a more detailed evaluation of liquidity risk.

Recent events, including filings and transcripts, are not disclosed in the available data, limiting the ability to assess recent operational or strategic developments.

Key takeaways

The company has a market capitalization of 2,457,676,175 CNY and a current market price of 3.95 CNY per share.
Analysts have assigned a mean price target of 7.77 CNY, indicating potential upside.
No immediate dilution pressure is observed, with basic and diluted shares outstanding being equal.
Liquidity risk could not be assessed due to missing balance-sheet data.
The company's profitability and return metrics are not available for comparison to industry benchmarks.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2026-03-30

FY 2026 · Full-year highlights

Revenue ¥1.05B, +30,9% YoY; Operating income +318,2% YoY.

Revenue¥1.05B+30,9 % YoY

Operating income¥104.0M+318,2 % YoY

Net income¥407.9M+174,6 % YoY

Free cash flow—

EPS—

Operating cash flow—

Financials

Income statement

Revenue¥1.05B

Gross profit¥376.2M

Operating income¥104.0M

Net income¥407.9M

Margins

Gross margin36.0%

Operating margin9.9%

Net margin39.0%

FCF margin—

Balance sheet

Total assets¥1.55B

Total liabilities¥565.7M

Total equity¥983.9M

Cash & equivalents¥549.6M

Long-term debt¥178.1M

P&L flow · revenue → net income

Highlights

▍Revenue ¥1.05B, +30,9% YoY
▍Operating income +318,2% YoY
▍Net income +174,6% YoY
▍Net margin 39.0%

Valuation FY

Market price

HK$3,80

Market cap

HK$2.46B

Enterprise valueⓘ

—

P/Eⓘ

6.0x

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,32

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-07 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,32
Revenue	—no estimate	—no estimate	1,4B CNY
Operating income	—no estimate	—no estimate	191,7M CNY

Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution3 analysts

Strong buy2

Buy1

Hold0

Sell0

Strong sell0

12-month price targetHK$7,77 · Median HK$7,77

Low HK$7,64High HK$7,90

Operating income · consensus191,7M CNY

EPS surprise

−16,5 %

reported vs consensus · miss

Revenue surprise

−22,5 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowHK$7,64

MeanHK$7,77

MedianHK$7,77

HighHK$7,90

SpotHK$3,80

+104.5 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Saint Bella Group Ltd Market data — financials · 2026-05-26
Saint Bella Group Ltd Market data — analyst estimates · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

2508.HKCanonical

HKEX · HKD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-03-30 15:19 UTCEARNINGSAnnual results — FY 2026 Revenue CNY 1.05B · Net CNY 407.9M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread